Skip Navigation

JNCI Journal of the National Cancer Institute 1988 80(16):1325-1328; doi:10.1093/jnci/80.16.1325
© 1988 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Richards, J. M.
Right arrow Articles by Vogelzang, N. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Richards, J. M.
Right arrow Articles by Vogelzang, N. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 80, No. 16, 1325-1328, October 19, 1988
© 1988 Oxford University Press

Phase I Study of Weekly 24-hour Infusions of Recombinant Human Interleukin-22

Jon M. Richards*, Ellen Barker, Jill Latta, Kathleen Ramming, Nicholas J. Vogelzang3,4

2Supported in part by Cetus Corporation and Public Health Service grant DK-13412 from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services.
3Joint Section of Hematology/Oncology, Department of Medicine, University of Chicago Chicago, IL

*Correspondence to: Dr. Jon M. Richards, Joint Section of Hematology/Oncology, Department of Medicine, University of Chicago, 5841 S. Maryland Ave., Box 420, Chicago, IL 60637.

Sixteen patients with metastatic melanoma or metastatic renal cell carcinoma were treated with six weekly 24-hour infusions of recombinant interleukin-2. At least three patients were treated at each dose, beginning at 3.0 mU/m2 for 24 hours each week for 6 weeks. Subsequent patients were treated at 4.5, 6.0, 8.0, and 10.0 mU/m2 for 24 hours. The incidence of diarrhea, rigors, rash, edema, and symptomatic hypotension was positively correlated with dose level. Symptomatic hypotension was dose limiting at the 10-mU/m2 level. Fever, nau-sea, and vomiting were seen at each dose level and could not be correlated with dose level. Lymphopenia and eosinophilia were observed at the completion of each 24-hour infusion, and an increase in peripheral blood absolute lymphocytes and eosinophils was observed over the 6-week treatment period. No thrombocytopenia was observed. No change in delayed-type hy-persensitivity [type IV) as determined by skin testing could be demostrated at any dose level. Natural killer cell cy-totoxicity of peripheral blood lymphocytes increased over the treatment period, but the increase was unrelated to dose level in the range studied. One minor response was documented in a patient with renal cell carcinoma.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. I. Clark, E. R. Gaynor, B. Martone, S. C. Budds, R. Manjunath, R. C. Flanigan, W. B. Waters, and J. A. Sosman
Daily Subcutaneous Ultra-Low-Dose Interleukin 2 with Daily Low-Dose Interferon-{{alpha}} in Patients with Advanced Renal Cell Carcinoma
Clin. Cancer Res., September 1, 1999; 5(9): 2374 - 2380.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.